US health panel recommends easing peptide restrictions

A panel of federal health advisers on Thursday narrowly voted to recommend that the Food and Drug Administration remove current barriers to pharmacy compounding of several peptides, a class of chemicals widely promoted by wellness influencers and celebrities for unproven uses like healing injuries and boosting energy. The panel's decision came despite strenuous objections from FDA staff scientists who said the chemicals have not been shown to be safe or effective.

Panel vote highlights divide on peptide safety

The outside experts, convened by the FDA, voted 8-6, with one abstention, to place peptides including BPC-157, TB-500 and KPV on the agency's list of substances considered safe for compounding by pharmacies. Compounding allows pharmacists to create customized versions of drugs, but the FDA currently restricts compounding of bulk substances that have not been formally approved. The panel's vote is not binding, but the FDA usually follows such recommendations.

If the FDA adopts the recommendation, telehealth companies are expected to significantly increase marketing of the peptides for wellness and cosmetic purposes. The vote tally reflected the unusual composition of the panel: prior to the meeting, more than half a dozen people with ties to the peptide industry were added, including doctors, pharmacists and consultants who work in the field.

Industry ties and divided opinions

David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, voted in favor of BPC-157, saying it was time to return decision-making to patients, physicians and pharmacists. However, panel members with academic backgrounds largely voted against the substances. Dr. Elizabeth Rebello of the University of Texas MD Anderson Center voiced concern that the panel was responding to market demand rather than solid science.

The vote is likely to embolden Health Secretary Robert F. Kennedy Jr., who has described himself as a big fan of peptides and has vowed to overturn restrictions put in place under the Biden administration. Kennedy's “Make America Healthy Again” agenda has attracted supporters like longevity influencer Gary Brecka, who sells peptides through his website.

Scientific concerns and regulatory backdrop

FDA staff scientists provided highly critical reviews ahead of the vote, noting there is little data that BPC-157, TB-500 and related chemicals can be safely used for medical purposes. Peptides are naturally occurring chains of amino acids that trigger hormones involved in growth, metabolism and healing. While some peptide-based drugs have been approved for conditions like diabetes and weight loss, most peptides sold online are marketed for unproven uses, often combined in so-called “stacks.”

Medical experts describe the marketplace as a “wild west” of unregulated drugs that carry risks of infection, allergic reactions and other harms. The panel is scheduled to vote on three more peptides on Friday.

Implications and next steps

The recommendation marks a significant shift in the regulatory environment for peptides, which have gained a strong following among celebrities such as podcaster Joe Rogan. If the FDA follows the panel's advice, it could open the door to broader availability of these chemicals, but it also raises questions about safety oversight. The agency is not required to adopt the recommendation, but its decision will be closely watched by both proponents and critics. The outcome could influence how other unregulated health products are treated in the future.